Etodolac sustained-release tablet and preparation method thereof
A technology of etodolac and sustained-release tablets, which can be used in pharmaceutical formulations, bone diseases, non-central analgesics, etc., and can solve the problems of packaging, transportation, and storage inconvenience, low drug release stability, and large gastrointestinal irritation, etc. problem, to achieve the effect of improving bioavailability, stabilizing therapeutic effect and easy absorption
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0026] A kind of etodolac sustained-release tablet is made of the following raw materials: 400mg etodolac, 150-390mg hypromellose , 10-50mg lubricant.
[0027] said The preferred weight ratio in raw materials is: 400mg etodolac, 385mg hypromellose , 15mg lubricant.
[0028] said Hypromellose can be one or both of the following types: 75hd100cr hypromellose 、75hd4000cr hypromellose 、75hd15000cr hypromellose 、100000cr Hypromellose.
[0029] said lubricant is One or both of magnesium stearate, talc, and silicon dioxide 。
[0030] Its production method includes the following steps:
[0031] Step 1: material preparation: according to the above mass ratio, etodolac is pulverized with a pulverizer, and passed through a 100-mesh sieve;
[0032] Step 2: Mixing: Weigh etodolac and hypromellose according to the above mass ratio, put them into a three-dimensional mixer and mix for 30 minutes to make medicine subdivisions, and take them o...
Embodiment 3
[0039] Indications of the present invention: for treating symptoms and signs of rheumatoid arthritis and osteoarthritis.
Embodiment 4
[0041] medicine interactions:
[0042] 1 1. It is not recommended to take this product with aspirin at the same time, so as not to increase the possibility of adverse events;
[0043] 2 1. The combined use of warfarin and non-steroidal anti-inflammatory drugs will increase the risk of gastrointestinal bleeding;
[0044] 3 , Non-steroidal anti-inflammatory drugs will competitively inhibit the accumulation of methotrexate in the kidney, which may increase the toxicity of methotrexate;
[0045] 4 , Non-steroidal anti-inflammatory drugs will weaken the antihypertensive effect of ACE inhibitors;
[0046] 5 1. When diuretics are used in combination with non-steroidal anti-inflammatory drugs, patients should be carefully observed for signs of renal failure;
[0047] 6 2. Lithium: Non-steroidal anti-inflammatory drugs inhibit the synthesis of renal prostaglandins. The use of such drugs will lead to increased lithium ion levels in plasma and decreased renal lithiu...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com